Nuvation Bio Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Insider Trading Arrangements
On June 21, 2024, Jerry Wang, AnHeart's Chief Executive Officer and member of the board of directors, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 130,886 shares of the Company's Common Stock. Pursuant to this plan, Mr. Wang may sell shares beginning October 21, 2024 and ending November 1, 2025.
On June 21, 2024, Kerry Wentworth, the Company's Chief Regulatory Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 303,920 shares of the Company's Common Stock. Pursuant to this plan, Ms. Wentworth may sell shares beginning October 21, 2024 and ending November 1, 2025.
On June 21, 2024, David Hanley, the Company's Chief Technical Operations Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 500,000 shares of the Company's Common Stock. Pursuant to this plan, Mr. Hanley may sell shares beginning October 21, 2024 and ending November 1, 2025.
On June 21, 2024, Gary Hattersley, the Company's Chief Scientific Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 398,935 shares of the Company's Common Stock. Pursuant to this plan, Mr. Hanley may sell shares beginning October 21, 2024 and ending November 1, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.